Adverse reactions of Trametinib

Most common adverse reactions (≥ 20%) for MEKINIST as a single agent  include rash, diarrhea, and lymphedema.

Most common adverse reactions (≥ 20%) for MEKINIST in combination with  dabrafenib include:  

Unresectable or metastatic melanoma: pyrexia, nausea, rash, chills,  diarrhea, vomiting, hypertension, and peripheral edema.

Adjuvant treatment of melanoma: pyrexia, fatigue, nausea, headache,  rash, chills, diarrhea, vomiting, arthralgia, and myalgia.

NSCLC: pyrexia, fatigue, nausea, vomiting, diarrhea, dry skin,  decreased appetite, edema, rash, chills, hemorrhage, cough, and dyspnea.

Adult patients with solid tumors: pyrexia, fatigue, nausea, rash, chills,  headache, hemorrhage, cough, vomiting, constipation, diarrhea, myalgia, arthralgia, and edema.

Pediatric patients with solid tumors: pyrexia, rash, vomiting, fatigue, dry  skin, cough, diarrhea, dermatitis acneiform, headache, abdominal pain,  nausea, hemorrhage, constipation, and paronychia.

Pediatric patients with LGG: pyrexia, rash, headache, vomiting,  musculoskeletal pain, fatigue, diarrhea, dry skin, nausea, hemorrhage,  abdominal pain, and dermatitis acneiform.

from FDA，2024.03